ArticleClinical and translational medicine2026
Dissecting diffuse large B-cell lymphoma heterogeneity: New insights from a state-specific molecular characterisation.
Article in Clinical and translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease.
methodsIn this study, we analysed a real-world cohort of 178 newly diagnosed DLBCL patients homogeneously treated with R-CHOP-like regimens, integrating RNA sequencing, targeted mutational profiling and digital deconvolution using the EcoTyper algorithm.
resultsFive malignant B-cell states (S1-S5) were identified, each reflecting distinct differentiation and transcriptional programs with prognostic relevance, S1 and S5 representing the most favourable and adverse subtypes, respectively. EcoTyper-defined lymphoma ecotypes (LE1-LE9), capturing co-associations between malignant and microenvironmental cell states, further refined prognostic classification, with LE1/LE2 and LE9 associated with the worst and most favourable prognosis, respectively. Both B-cell states and LE retained independent prognostic value in multivariable analyses after adjusting for the cell of origin and the revised international prognostic index. Mutational profiling revealed state-specific patterns: S1 harboured mutations in genes involved in epigenetic regulation, cytoskeletal organisation and tumour microenvironment (TME) interactions (CREBBP, EZH2 and ACTB), whereas S5 was enriched for mutations promoting survival signalling, immune evasion and differentiation blockade (MYD88, CD79B and TP53). In vitro validation using human five DLBCL cell lines independently recapitulated the S1 and S5 transcriptomic states, supporting the existence of intrinsic, cell-autonomous biological programs. Pathway analysis indicated that S1 was linked to cell adhesion, extracellular matrix remodelling and inflammatory signalling, while S5 displayed enrichment of cell-cycle deregulation, metabolic reprogramming and immune evasion. Accordingly, S1 tumours appear reliant on TME interactions, whereas S5 tumours adopt a predominantly TME independent, intrinsically aggressive phenotype.
conclusionsCollectively, these findings delineate a biologically coherent framework linking pathway deregulation with cell state and ecotype-specific mutational landscapes, refining DLBCL risk classification and adding an additional dimension to conventional prognostic models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.